The Th2 cytokine IL-4 is not required for the progression of antibody- dependent autoimmune myasthenia gravis

Journal of Immunology

Volumn 161, Issue 6, 1998, Pages 2856-2862

  Balasa, Balaji ^a   Deng, Caishu ^b   Lee, Jae ^a   Christadoss, Premkumar ^b   Sarvetnick, Nora ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; INTERLEUKIN 4; NICOTINIC RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HELPER CELL; HUMORAL IMMUNITY; LYMPH NODE CELL; LYMPHOCYTE PROLIFERATION; MOUSE; MUSCLE WEAKNESS; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; AUTOANTIBODIES; CYTOKINES; DISEASE PROGRESSION; GENE DELETION; IMMUNIZATION; IMMUNODOMINANT EPITOPES; IMMUNOGLOBULIN G; INTERLEUKIN-4; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; MYASTHENIA GRAVIS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RECEPTORS, NICOTINIC; T-LYMPHOCYTE SUBSETS; TH2 CELLS; TORPEDO;

EID: 0032530374     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Christadoss, P. 1989. Immunogenetics of experimental autoimmune myasthenia gravis. Crit. Rev. Immunol. 9:247.
2. Penn, A. S., D. P. Richman, R. L. Ruff, and V. A. Lennon. 1993. Myasthenia gravis and related disorders: experimental and clinical aspects. Ann. NY Acad. Sci. 681:198.
3. Lindstrom, J., D. Shelton, and Y. Fujii. 1988. Myasthenia gravis. Adv. Immunol. 42:233.
4. Protti, M. P., A. A. Manfredi, R. M. Horton, M. Bellone, and B. M. Conti-Tronconi. 1993. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol. Today 14:363.
5. Fuchs, S., D. Nevo, and R. Tarrab-Hazdai. 1976. Strain differences in the autoimmune response of mice to acetylcholine receptors. Nature 263:329.
6. Berman, P. W., and J. Patrick. 1980. Experimental myasthenia gravis: a murine system. J. Exp. Med. 151:204.
7. Kaul, R., M. Shenoy, E. Goluszko, and P. Christadoss. 1994. Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. J. Immunol. 152:3152.
8. Lennon, V. A., J. M. Lindstrom, and M. E. Seybold. 1975. Experimental autoimmune myasthenia: a model of myasthenia gravis in rats and guinea pigs. J. Exp. Med. 141:1365.
9. Christadoss, P., and M. J. Dauphinee. 1986. Immunotherapy for myasthenia gravis: a murine model. J. Immunol. 136:2436.
10. + T cells are essential to induce experimental autoimmune myasthenia gravis. J. Exp. Med. 184:349.
11. Kao, I., and D. B. Drachman. 1977. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science 199:527.
12. Toyka, D.V., D. B. Drachman, A. Pestronk and I. Kao. 1975. Myasthenia gravis: passive transfer from man to mouse. Science 190:397.
13. Lindstrom, J.M., A. G. Engel, M. E. Seybold, V.A. Lennon, and E. H. Lambert. 1976. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine receptor antibodies. J. Exp. Med. 144:739.
14. Stanely, E. F., and D. B. Drachman. 1978. Effect of myasthenic immunoglobulin on acetylcholine receptors of intact mammalian neuromuscular junctions. Science 200:1285.
15. Lennon, V. A., and E. H. Lambert. 1980. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature 285:238.
16. Gomez, C. M., and D. P. Richman. 1985. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J. Immunol. 135:234.
17. Balasa, B., C. Deng, J. Lee, L. M. Bradley, D. K. Dalton, P. Christadoss, and N. Sarvetnick. 1997. Interferon γ (IFN-γ) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186:385.
18. Murakami, M., and T. Honjo. 1997. Transgenic mouse models for B-cell dominant autoimmune diseases. Curr. Opin. Immunol. 9:846.
19. Kopf, M., G. Le Gros, M. Bachmann, M. C. Lamers, H. Bluethemann, and G. Kohler. 1993. Disruption of the murine IL-4 gene blocks Th2 responses. Nature 362:245.
20. Lindstrom, J. M., B. L. Einerson, and S. Tzartos. 1981. Production and assay of antibodies to acetylcholine receptors. Methods Enzymol. 74:432.
21. Rao, V. P., B. Balasa, and G. Carayanniotis. 1994. Mapping of thyroglobulin epitopes: presentation of a 9-mer pathogenic peptide by different mouse MHC class II isotypes. Immunogenetics 40:352.
22. Deng, C., E. Goluszko, S. Baron, B. Wu, and P. Christadoss. 1996. Interferon α therapy is effective in suppressing the clinical experimental myasthenia gravis. J. Immunol. 157:5675.
23. Shenoy, M., M. Oshima, M. Z. Atassi, and P. Christadoss. 1993. Suppression of experimental autoimmune myasthenia gravis by epitope-specific neonatal tolerance to synthetic region α 146-162 of acetylcholine receptor. Clin. Exp. Immunol. 66:230.
24. Shenoy, M., E. Goluszko, and P. Christadoss. 1994. The pathogenic role of acetylcholine receptor α chain epitope within α146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice. Clin. Immunol. Immunopathol. 73:338.
25. Wu, B., C. Deng, E. Goluszko, and P. Christadoss. 1997. Tolerance to a dominant T cell epitope in the acetylcholine receptor molecule induces epitope spread and suppresses murine myasthenia gravis. J. Immunol. 159:3016.
26. Rosenberg, J. S., M. Oshima, and M. Z. Atassi. 1996. B-cell activation in vitro by helper T cells specific to region α146-162 of Torpedo californica nicotinic acetylcholine receptor. J. Immunol. 157:3192.
27. Lawrence, R., J. E. Allen, W. F. Gregory, M. Kopf, and R. M. Maizels. 1995. Infection of IL-4-deficient mice with the parasite nematode Brugia malayi demonstrates that host resistance is not dependent on a T helper 2-dominated immune response. J. Immunol. 154:5995.
28. Kopf, M., F. Brombacher, G. Kohler, G. Kienzle, K.-H. Widmann, K. Lefrang, C.Humborg, B. Ledermann, and W. Solbach. 1996. IL-4-deficient BALB/c mice resist infection with Leishmania major. J. Exp. Med. 184:1127.
29. Yokoi, T., B. Mulac-Jerivic, J.-I. Kurisaki, and M. Z. Atassi. 1987. T lymphocyte recognition of acetylcholine receptor, localization of the full T cell recognition profile on the extracellular part of the α chain of Torpedo californica acetylcholine receptor. Eur. J. Immunol. 17:1697.
30. Bellone, M., N. Ostlie, S. Lei, and B. M. Conti-Tronconi. 1991. Experimental myasthenia gravis in congenic mice: sequence mapping and H-2 restriction of T helper epitopes on the α subunits of Torpedo californica and murine acetylcholine receptors. Eur. J. Immunol. 21:2303.
31. + cells. J. Immunol. 151:1025.
32. Infante, A. J., H. Levcovitz, V. Gordon, K. A. Wall, P. A. Thomson, and K. A. Krolick. 1992. Preferential use of a T cell receptor Vβ gene by acetylcholine receptor reactive T cells from myasthenia gravis-susceptible mice. J. Immunol. 148:3385.
33. b strains. J. Immunol. 154:3603.
34. Vincent, A., and J. Newsom-Davis. 1980. Anti-acetylcholine receptor antibodies. J. Neurosurg. Psychol. 43:590.
35. Coffman, R. L., B. W. Seymour, D. A. Lebman, D. D. Hiraki, J. A. Christiansen, B. Schrader, H. M. Cherwinski, H. F. J. Savelkoul, F. D. Finkelman, M. W. Bond, and T. R. Mosmann. 1988. The role of helper T cell products in mouse B cell differentiation and isotype regulation. Immunol. Rev. 102:5.
36. Gu, D., L. Wogensen, N. A. Calcutt, C. Xia, S. Zhu, J. P. Merlie, H. S. Fox, J. Lindstrom, H. C. Powell, and N. Sarvetnick. 1995. Myasthenia gravis-like syndrome induced by expression of interferon γ in the neuromuscular junction. J. Exp. Med. 181:547.
37. Dedhia, V., E. Goluszko, B. Wu, C. Deng, and P. Christadoss. 1998. The effect of B cell deficiency on the immune response to acetylcholine receptor and the development of experimental autoimmune myasthenia gravis. Clin. Immunol. Immunopathol. 87:266.
38. Peng, S. L., J. Moslehi, and J. Craft. 1997. Role of interferon-γ and interleukin-4 in murine lupus. J. Clin. Invest. 99:1936.
39. Balomenos, D., R. Rumold, and A. N. Theofilopoulos. 1998. IFN-γ is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J. Clin. Invest. 101:364.
40. Haas, C., B. Ryffel, and M. Le Hir. 1997. IFN-γ is essential for the development of autoimmune glomerulonephritis in MRL/lpr mice. J. Immunol. 158:5484.
41. Seery, J. P., J. M., Carroll, V. Cattell, and F. M. Watt. 1997. Antinuclear autoantibodies and lupus nephritis in transgenic mice expressing IFN-γ m the epidermis. J. Exp. Med. 186:1451.
42. Kono, D. H., D. Balemenos, D. L. Pearson, M. S. Park, B. Hildebrandt, P. Hultman, and K. M. Pollard. 1998. The prototypic Th2 autoimmunity induced by mercury is dependent on IFN-γ and not Th1/Th2 imbalance. J. Immunol. 161:234.
43. Hultgren, B., X. Huang, N. Dybdal, and T. A. Stewart. 1996. Genetic absence of γ-interferon delays but does no, prevent diabetes in NOD mice. Diabetes 45:812.
44. Ferber, I. A., S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Stemman, Dalton, D. and C. G. Fathman. 1996. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis. J. Immunol. 156:5.
45. Jones, L. S., L. V. Rizzo, R. K. Agarwal, T. K. Tarrant, C.-C. Chan, B. Wiggert, and R. R. Caspi. 1997. IFN-γ-deficient mice develop experimental autoimmune uveitis in the context of deviant effector response. J. Immunol. 158:5997.
46. Manoury-Schwartz, B., G. Chiocchia, N. Bessis, O. Abehsira-Amar, F. Batteux, S. Muller, S. Huang, M. C. Boissier, and C. Fournier. 1997. High susceptibility to collagen-induced arthritis in mice lacking IFN-γ receptors. J. Immunol. 158: 5501.
47. Alimi, E., S. Huang, M.-P. Brazillet, and J. Charreire. 1998. Experimental autoimmune thyroiditis (EAT) in mice lacking the IFN-γ receptor gene. Eur. J. Immunol. 28:201.
48. Liblau R., R. L. Steinman, and S. Brocke. 1997. Experimental autoimmune encephalomyelitis in IL-4-deficient mice. Int. Immunol. 9:799.
49. Tang, H., C. C. Sharp, K. E. Peterson, and H. Braley-Mullen. 1998. Induction of granulomatous experimental autoimmune thyroiditis in IL-4 gene-disrupted mice. J. Immunol. 160:155.
50. Segal, B. M., B. K. Dwyer, and E. M. Shevach. 1998. An interleukin (IL)-10/ IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. J. Exp. Med. 187:537.
51. Noben-Trauth, N., P. Kropf, and I. Muller. 1996. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 271:987.
52. Guler, M. L., J. D. Gorham, C.-S. Hseih, A. J., Mackey, R G. Steen, W. F. Dietrich, and K. M. Murphy. 1996. Genetic susceptibility to Leishmania: IL-12 responsiveness in Th1 cell development. Science 271:984.
53. Pearlman E., J. H. Lass, D. S. Bardenstein, M. Kopf, F. E. Hazlett, E. Diaconu, and J. W. Kazura. 1995. IL-4 and Th2 cells are required for development of experimental onchocercal keratitis (river blindness). J. Exp. Med. 182:931.
54. Lawrence, R. A., J. A. Allen, W. F. Gregory, M. Kopf, and R. M. Maizels, 1995. Infection of IL-4-deficient mice with the parasitic nematode Brugia malayi demonstrates that host resistance is not dependent on a T helper 2-dominated immune response. J. Immunol. 154:5995.
55. Metwali, A., D. Elliott, A. M. Blum, J. Li, M. Sandor, R. Lynch, N. Noben-Trauth, and J. V. Weinstock. 1996. The granulomatous response in murine Schistosomiasis mansoni does not switch to Th1 in IL-4-deficient C57BL/6 mice. J. Immunol. 157:4546.
56. Everest, P., J. Allen, A. Papakonstantinopoulou, P. Mastroeni, M. Roberts, and G. Dougan. 1997. Salmonella typhimurium infections in mice deficient in interleukin-4 production. J. Immunol. 159:1820.
57. Karachunski, P., N. S. Ostile, D. K. Okita, and B. M. Conti-Fine. 1997. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 100:3027.
58. Wang, Z. Y., J. Qiao, A. Melms, and H. Link. 1993. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis. Cell. Immunol 152:394.
59. Zhang, G.-X., C.-G. Ma, B.-G. Xiao, P. H. van de Meide, and H. Link. 1996. Autoreactive T cell responses and cytokine patterns reflect resistance to experimental autoimmune myasthenia gravis in Wistar Furth rats. Eur. J. Immunol. 26:2552.
60. Kuhn, R., K. Rajewsky, and W. Muller. 1991. Generation and analysis of interleukin-4 deficient mice. Science 254:707.
61. Le Gros, G., S. Z. Ben Sasson, R. Seder, F. D. Finkelman, and W. E. Paul. 1990. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for generation of IL-4 producing cells. J. Exp. Med. 172:921.
62. Swam, S. L., A. D. Weinberg, M. English, and G. Huston. 1990. IL-4 directs the development of different subsets of helper T cells. J. Immunol. 145:3796.
63. Zhang, G. X., V. Navikas, and H. Link. 1997. Cytokines and pathogenesis of myasthenia gravis. Muscle Nerve 20:543.
64. Shi, F. D., G. X. Zhang, X. F. Bai, P. H. Van Der Meide, and H. Link. 1997. Cellular mRNA expression of interferon-gamma (IFN-γ) IL-4 and IL-10 relates to resistance to experimental autoimmune myasthenia gravis (EAMG) in young Lewis rats. Clin. Exp. Immunol. 108:523.
65. Pelletier, L., R. Pasquier, J. Rossert, M. C. Vial, C. Mandet, and P. Duret. 1988. Autoreactive T cells in mercury-induced autoimmunity: ability to induce the autoimmune disease. J. Immunol 140:750.
66. Prigent, P., A. Saoudi, C. Pannetier, P. Graber, J. Y. Bonnefoy, P. Duret, and F. Hirsch. 1995. Mercuric chloride, a chemical responsible for T helper cell (Th2)-mediated autoimmunity in Brown Norway rats, directly triggers T cells to produce interleukin-4. J. Clin. Invest. 96:1484.
67. Yoshikawa, H., E. H. Lambert, D. R. Walser-Kuntz, Y. Yasukawa, D. J. McCormick, and V. A. Lennon. 1997. A 17-mer self-peptide of acetylcholine receptor binds to B cell MHC class II, activates helper T cells, and stimulates autoantibody production and electrophysiologic signs of myasthenia gravis. J. Immunol. 159:1570.
68. Abbas, A. K., K. M. Murphy, and A. Sher. 1996. Functional diversity of helper T lymphocytes. Nature 383:787.
69. Wogensen, L., M.-S. Lee, and N. Sarvetnick. 1994. Production of interleukin 10 by islet cellls accelerates immune-mediated destruction β cells in nonobese diabetic mice. J. Exp. Med. 179:1379.
70. Mueller, R., J. D. Davies, T. Krahl, and N. Sarvetnick. 1996. IL-4 expression by grafts from transgenic mice fails to prevent allograft rejection. J. Immunol. 159: 1599.